A study to test whether different doses of BI 456906 help people with overweight or obesity to lose weight

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 520

Inclusion Criteria

1. Adult = 18 years and < 75 years of age at screening
2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
3. Obesity or Overweight defined as BMI =27 kg/m2 at screening
4. A minimum absolute body weight of 70 kg for females and 80 kg for males at screening
5. Male or female participants. Women of childbearing potential (WOCBP)1 must be willing and able to use two forms of effective contraception where at least one form is highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
6. Patients must have undergone at least one previous unsuccessful nonsurgical weight-loss attempt per investigator’s judgement
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 200
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 150

Exclusion Criteria

1. Body weight change of over +/- 5% or more in the past 12 weeks prior to randomization. There must be documentation of weight in the past 12 weeks before randomization.
2. Obesity induced by an endocrinologic disorder (e.g. Cushing Syndrome)
3. A HbA1c = 6.5% at screening or diagnosed with type 1 or type 2 diabetes mellitus
4. Exposure to GLP-1Ra based therapies within three months prior to screening
5. Any suicidal behaviour in the past 2 years, any suicidal ideation of type 4 or 5 in the CSSRS within 3 months before screening, or during screening period
6. History of major depressive disorder within 2 years before randomization
7. Major depressive symptoms (defined as a screening Patient Health Questionnaire-9 [PHQ-9] score =15) at screening and/or during screening period
8. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders at screening
9. Screening calcitonin =20 pg/mL
10. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, manifest hypo- or hyperthyroidism at screening
11. History of chronic or acute pancreatitis or elevation of serum lipase/amylase > 2x ULN, or fasting serum triglyceride levels of > 500 mg/dl at screening
12. Treatment with medication that potentially induce a change in body weight (e.g., steroids, antipsychotics) , or anti-obesity medication including over-the-counter [OTC] medications, or participating in an organized weight loss program (e.g. Weight Watchers® or Noom® ) within 3 months before screening
13. Prior surgery of the GI tract that could interfere with body weight (including minimally invasive/endoscopic bariatric devices, bariatric surgery) except appendectomy and simple hernia repair before randomization
14. Resting Heart Rate >100 bpm at screening or randomisation
15. Systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 95 mmHg at screening

Further criteria apply.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials